Spyre Therapeutics, Inc.

NASDAQ:SYRE

Biotechnology

Healthcare
$101.46 +1.38%

+$1.21 today

Market cap
$9.64B
Beta
3.06
P/E (TTM)
-171.1
EPS (TTM)
-$0.52
52W Low $14.00High $91.04

Volume 1.37M

Average 1.17M

SYRE Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Spyre Therapeutics, Inc.NASDAQ: SYRE

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares growth accelerates

Q3 FY2026 weighted avg shares of 346.05M shares rose 472.8% year over year, ahead of the +155.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 308.4% from the prior quarter. Over 3 fiscal years it compounded at +166.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +472.8% holds above the trailing-twelve-month pace of +155.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
346.05M+308.4% QoQ
Last fiscal yearDec 2025
64.06M+36.2% YoY
LTMSep 2026
146.1M+155.9% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+472.8%——
1 year+36.2%——
3-year CAGR+166.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
64.06M USD
Year-over-year change
+36.2%
4-year CAGR
+122.2%

Weighted Avg Shares vs competitors

How SYRE compares with its peers on the latest reported figures

  • SYRE's LTM Sep 2026 weighted avg shares of 146.1M shares is the 2nd highest of the 9 companies compared; the peer median is 61.42M shares.
  • Its year-over-year change of +155.9% is the highest of 9, against a peer median of +7.2%.
  • Over three fiscal years its annual growth of +166.8% compares with a peer median of +15.0%.
SYRE Competitors Peer median
Weighted Avg Shares for SYRE and competitors
Company Period LTM YoY 3-year CAGR
ARDXArdelyx, Inc.LTM Mar 2026242.83M +2.6%+15.0%
SYRESpyre Therapeutics, Inc.LTM Sep 2026146.1M +155.9%+166.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ABVXAbivax S.A.FY202569.53M +10.3%+53.9%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
UPBUpstream Bio, Inc.LTM Mar 202654.07M +4.2%+14.0%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding SYRE) 61.42M+7.2%+15.0%

Competitors are the stored peer set for SYRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.74M2.33M886K00
Cost of Revenue0000171.65M
Gross Profit18.74M2.33M886K0(171.65M)
Gross Margin100.0%100.0%100.0%——
Research & Development57.07M58.58M89.5M162.79M171.65M
Selling, General & Admin27.32M28.53M39.95M45.78M47.91M
Operating Expenses84.39M87.11M243.19M208.57M37.91M
Depreciation & Amortization1.58M1.96M744K010M
EBITDA(64.08M)(81.99M)(127.82M)(207.97M)(209.56M)
EBITDA Margin-342.0%-3520.3%-14426.6%——
Operating Income(65.65M)(84.78M)(242.3M)(208.57M)(209.56M)
Operating Margin-350.3%-3640.2%-27348.0%——
Interest Income111K837K6.15M21.31M24.89M
Interest Expense00000
Other Income / Expenses(11K)830K(96.51M)599K54.34M
Income Before Tax(65.66M)(83.95M)(338.82M)(207.97M)(155.22M)
Pre-Tax Margin-350.4%-3604.6%-38241.1%——
Income Tax Expense141K(136K)(26K)51K(15K)
Net Income(65.8M)(83.82M)(338.79M)(208.02M)(155.2M)
Net Margin-351.1%-3598.8%-38238.1%——
EPS (Basic)(25.02)(24.86)(46.15)(3.18)(1.98)
EPS (Diluted)(25.02)(24.86)(46.15)(3.18)(1.98)
Weighted Avg Shares2.63M3.37M6.9M47.03M64.06M
Weighted Avg Shares (Diluted)2.63M3.37M6.9M47.03M64.06M

Spyre Therapeutics, Inc.

NASDAQ:SYRE

Intrinsic Alpha fair value

Locked

Current Price

$101.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.